• Rajiv Jalan, Marco Pavesi, Faouzi Saliba, Alex Amorós, Javier Fernandez, Peter Holland-Fischer, Rohit Sawhney, Rajeshwar Mookerjee, Paolo Caraceni, Richard Moreau, Pere Ginès, Francois Durand, Paolo Angeli, Carlo Alessandria, Wim Laleman, Jonel Trebicka, Didier Samuel, Stefan Zeuzem, Thierry Gustot, Alexander L Gerbes, Julia Wendon, Mauro Bernardi, Vicente Arroyo, and CANONIC Study Investigators; EASL-CLIF Consortium.
• Liver Failure Group, Institute for Liver and Digestive Health, Royal Free Hospital, London, United Kingdom.
• J. Hepatol. 2015 Apr 1;62(4):831-40.

Background & AimsCirrhotic patients with acute decompensation frequently develop acute-on-chronic liver failure (ACLF), which is associated with high mortality rates. Recently, a specific score for these patients has been developed using the CANONIC study database. The aims of this study were to develop and validate the CLIF-C AD score, a specific prognostic score for hospitalised cirrhotic patients with acute decompensation (AD), but without ACLF, and to compare this with the Child-Pugh, MELD, and MELD-Na scores.MethodsThe derivation set included 1016 CANONIC study patients without ACLF. Proportional hazards models considering liver transplantation as a competing risk were used to identify score parameters. Estimated coefficients were used as relative weights to compute the CLIF-C ADs. External validation was performed in 225 cirrhotic AD patients. CLIF-C ADs was also tested for sequential use.ResultsAge, serum sodium, white-cell count, creatinine and INR were selected as the best predictors of mortality. The C-index for prediction of mortality was better for CLIF-C ADs compared with Child-Pugh, MELD, and MELD-Nas at predicting 3- and 12-month mortality in the derivation, internal validation and the external dataset. CLIF-C ADs improved in its ability to predict 3-month mortality using data from days 2, 3-7, and 8-15 (C-index: 0.72, 0.75, and 0.77 respectively).ConclusionsThe new CLIF-C ADs is more accurate than other liver scores in predicting prognosis in hospitalised cirrhotic patients without ACLF. CLIF-C ADs therefore may be used to identify a high-risk cohort for intensive management and a low-risk group that may be discharged early.Copyright © 2015 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

32 keywords...

hide…